PROMIS® scores in operative metastatic bone disease patients: A multicenter, prospective study

Alan T. Blank, Daniel M. Lerman, Sara Shaw, Farnaz Dadrass, Yue Zhang, Wei Liu, Man Hung, Kevin B. Jones, R Randall

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The prevalence of metastatic bone disease (MBD) grows each year as treatments improve. Little has been published about functional and pain outcomes in this group after surgery. Patient-Reported Outcomes Measurement Information System (PROMIS®) can collect information, in just minutes, about patient's physical, mental, and social health. This study evaluated PROMIS® pain and functional scores in surgically treated patients with MBD. Methods: Basic demographics and PROMIS® scores were recorded from a total of 13 patients at 9 periods of time over 6 months. Results: The average change in physical function at week 1 was −2.5 (standard deviation [SD] = 5.4), at 2 weeks 1.7 (SD = 7.6), after 4 weeks 6.9 (SD = 10), after 6 weeks 6.4 (SD = 10.9), after 10 weeks 15.3 (SD = 3.1), and after 3 months 8.6 (SD = 7.6). The average change in pain inference at week 1 was −1.2 (SD = 7.3), at 2 weeks −2.1 (SD = 9.5), after 4 weeks −12.6 (SD = 4.5), after 6 weeks −8.3 (SD = 10.2), after 10 weeks −16.6 (SD = 4.3), and after 3 months −11.4 (SD = 8.2). Conclusions: PROMIS® provides a feasible means to collect data in this population. Trends of improved function and decreased pain were seen after surgery. Continuing this study will hopefully elucidate more insight into the surgical treatment of MBD.

Original languageEnglish (US)
Pages (from-to)532-535
Number of pages4
JournalJournal of Surgical Oncology
Volume118
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Bone Diseases
Information Systems
Multicenter Studies
Prospective Studies
Pain
Mental Health
Demography
Patient Reported Outcome Measures
Therapeutics
Population

Keywords

  • functional outcomes
  • metastatic bone disease (MBD)

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

PROMIS® scores in operative metastatic bone disease patients : A multicenter, prospective study. / Blank, Alan T.; Lerman, Daniel M.; Shaw, Sara; Dadrass, Farnaz; Zhang, Yue; Liu, Wei; Hung, Man; Jones, Kevin B.; Randall, R.

In: Journal of Surgical Oncology, Vol. 118, No. 3, 01.09.2018, p. 532-535.

Research output: Contribution to journalArticle

Blank, AT, Lerman, DM, Shaw, S, Dadrass, F, Zhang, Y, Liu, W, Hung, M, Jones, KB & Randall, R 2018, 'PROMIS® scores in operative metastatic bone disease patients: A multicenter, prospective study', Journal of Surgical Oncology, vol. 118, no. 3, pp. 532-535. https://doi.org/10.1002/jso.25159
Blank, Alan T. ; Lerman, Daniel M. ; Shaw, Sara ; Dadrass, Farnaz ; Zhang, Yue ; Liu, Wei ; Hung, Man ; Jones, Kevin B. ; Randall, R. / PROMIS® scores in operative metastatic bone disease patients : A multicenter, prospective study. In: Journal of Surgical Oncology. 2018 ; Vol. 118, No. 3. pp. 532-535.
@article{87a9ec902f4e48578ff9f14647ece539,
title = "PROMIS{\circledR} scores in operative metastatic bone disease patients: A multicenter, prospective study",
abstract = "Background: The prevalence of metastatic bone disease (MBD) grows each year as treatments improve. Little has been published about functional and pain outcomes in this group after surgery. Patient-Reported Outcomes Measurement Information System (PROMIS{\circledR}) can collect information, in just minutes, about patient's physical, mental, and social health. This study evaluated PROMIS{\circledR} pain and functional scores in surgically treated patients with MBD. Methods: Basic demographics and PROMIS{\circledR} scores were recorded from a total of 13 patients at 9 periods of time over 6 months. Results: The average change in physical function at week 1 was −2.5 (standard deviation [SD] = 5.4), at 2 weeks 1.7 (SD = 7.6), after 4 weeks 6.9 (SD = 10), after 6 weeks 6.4 (SD = 10.9), after 10 weeks 15.3 (SD = 3.1), and after 3 months 8.6 (SD = 7.6). The average change in pain inference at week 1 was −1.2 (SD = 7.3), at 2 weeks −2.1 (SD = 9.5), after 4 weeks −12.6 (SD = 4.5), after 6 weeks −8.3 (SD = 10.2), after 10 weeks −16.6 (SD = 4.3), and after 3 months −11.4 (SD = 8.2). Conclusions: PROMIS{\circledR} provides a feasible means to collect data in this population. Trends of improved function and decreased pain were seen after surgery. Continuing this study will hopefully elucidate more insight into the surgical treatment of MBD.",
keywords = "functional outcomes, metastatic bone disease (MBD)",
author = "Blank, {Alan T.} and Lerman, {Daniel M.} and Sara Shaw and Farnaz Dadrass and Yue Zhang and Wei Liu and Man Hung and Jones, {Kevin B.} and R Randall",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/jso.25159",
language = "English (US)",
volume = "118",
pages = "532--535",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - PROMIS® scores in operative metastatic bone disease patients

T2 - A multicenter, prospective study

AU - Blank, Alan T.

AU - Lerman, Daniel M.

AU - Shaw, Sara

AU - Dadrass, Farnaz

AU - Zhang, Yue

AU - Liu, Wei

AU - Hung, Man

AU - Jones, Kevin B.

AU - Randall, R

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: The prevalence of metastatic bone disease (MBD) grows each year as treatments improve. Little has been published about functional and pain outcomes in this group after surgery. Patient-Reported Outcomes Measurement Information System (PROMIS®) can collect information, in just minutes, about patient's physical, mental, and social health. This study evaluated PROMIS® pain and functional scores in surgically treated patients with MBD. Methods: Basic demographics and PROMIS® scores were recorded from a total of 13 patients at 9 periods of time over 6 months. Results: The average change in physical function at week 1 was −2.5 (standard deviation [SD] = 5.4), at 2 weeks 1.7 (SD = 7.6), after 4 weeks 6.9 (SD = 10), after 6 weeks 6.4 (SD = 10.9), after 10 weeks 15.3 (SD = 3.1), and after 3 months 8.6 (SD = 7.6). The average change in pain inference at week 1 was −1.2 (SD = 7.3), at 2 weeks −2.1 (SD = 9.5), after 4 weeks −12.6 (SD = 4.5), after 6 weeks −8.3 (SD = 10.2), after 10 weeks −16.6 (SD = 4.3), and after 3 months −11.4 (SD = 8.2). Conclusions: PROMIS® provides a feasible means to collect data in this population. Trends of improved function and decreased pain were seen after surgery. Continuing this study will hopefully elucidate more insight into the surgical treatment of MBD.

AB - Background: The prevalence of metastatic bone disease (MBD) grows each year as treatments improve. Little has been published about functional and pain outcomes in this group after surgery. Patient-Reported Outcomes Measurement Information System (PROMIS®) can collect information, in just minutes, about patient's physical, mental, and social health. This study evaluated PROMIS® pain and functional scores in surgically treated patients with MBD. Methods: Basic demographics and PROMIS® scores were recorded from a total of 13 patients at 9 periods of time over 6 months. Results: The average change in physical function at week 1 was −2.5 (standard deviation [SD] = 5.4), at 2 weeks 1.7 (SD = 7.6), after 4 weeks 6.9 (SD = 10), after 6 weeks 6.4 (SD = 10.9), after 10 weeks 15.3 (SD = 3.1), and after 3 months 8.6 (SD = 7.6). The average change in pain inference at week 1 was −1.2 (SD = 7.3), at 2 weeks −2.1 (SD = 9.5), after 4 weeks −12.6 (SD = 4.5), after 6 weeks −8.3 (SD = 10.2), after 10 weeks −16.6 (SD = 4.3), and after 3 months −11.4 (SD = 8.2). Conclusions: PROMIS® provides a feasible means to collect data in this population. Trends of improved function and decreased pain were seen after surgery. Continuing this study will hopefully elucidate more insight into the surgical treatment of MBD.

KW - functional outcomes

KW - metastatic bone disease (MBD)

UR - http://www.scopus.com/inward/record.url?scp=85052664792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052664792&partnerID=8YFLogxK

U2 - 10.1002/jso.25159

DO - 10.1002/jso.25159

M3 - Article

C2 - 30114336

AN - SCOPUS:85052664792

VL - 118

SP - 532

EP - 535

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -